Everything below concerns peptide backbone. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
The Chinese People's Armed Police Coast Guard Bureau, also abbreviated as China Coast Guard is the agency for maritime search and rescue and law enforcement in the territorial waters of the People's Republic of China. The China Coast Guard was formerly the maritime branch of the People's Armed Police (PAP) Border Security Force under the Ministry of Public Security until 2013. In March 2013, China announced it would form a unified Coast Guard commanded by the State Oceanic Administration. This renewed Coast Guard has been in operation since July 2013. As of 1 July 2018, the China Coast Guard was transferred from civilian control of the State Council and the State Oceanic Administration, to the People's Armed Police, ultimately placing it under the command of the Central Military Commission (CMC). According to Joel Wuthnow of the Institute for National Strategic Studies, the Coast Guard Command within the People's Armed Police possibly is of Corps Leader Grade, led by a Commandant who usually holds the rank of major general. In June 2018, China Coast Guard was granted maritime rights and law enforcement akin civilian law enforcement agencies in order to carry out contrast of illegal activities, keep peace and order, as well as safeguarding security at sea, when performing duties related to the use of marine resources, protection of marine environment, regulation of fishery, and anti-smuggling. There are currently 3 regional bureaus:
=== Prenatal development === The prenatal portion of tissue-resident dermal macrophages is produced from yolk-sac derived precursors. The generation of dermal macrophages results from primitive haematopoiesis or definitive haematopoiesis. Primitive haematopoiesis allows the generation of yolk-sac derived macrophages and subsequent release into the foetal bloodstream for tissue infiltration and colonisation. The infiltration of the skin by yolk-sac derived macrophages occurs as soon as 8.5 days after fertilisation. Different gene expressions regulate this process. It is independent of the MYB gene and dependent on the PU.1 gene. Definitive haematopoiesis occurs from 11 days and onwards after fertilisation. Monocytes are produced from haematopoietic stem cells in the liver, and they subsequently infiltrate the skin via the foetal bloodstream. In this process, cytokines like CSF1 are essential in facilitating the differentiation of monocytes into tissue-resident dermal macrophages and their survival. Therefore, the differentiation of monocytes to dermal macrophages is CSF-1/CSF1R dependent. The level of dermal macrophages from prenatal development remains detectible through constant, slow proliferation.
== Chemical composition and reservoirs == Third-hand smoke and its components have been detected in various indoor environments. The possibility of nitrosamine formation on vehicular surfaces was identified via the spraying of "high but reasonable" levels of nitrous acid (about 4–12 times the levels typically found in homes) onto cellulose substrates and wiping surfaces in a vehicle that had experienced heavy smoking. Similar results were found when cellulose substrates were kept (without wiping) in the vehicle for three days when smoking occurred. Additionally, the persistence of various third-hand smoke components was quantified on wool, cotton, and polyester fibers with THS the most persistent on wool and least persistent on polyester. Washing clothing without detergent was found to remove some THS, though a substantial amount remained after standard laundering. Because of the growing resolving power and improved detection limits of analytical instruments (sometimes called the "vanishing zero" phenomenon), studies have demonstrated the transport of THS into other spaces via various media. For instance, third-hand smoke signatures have been detected in particles, which can effectively transport such compounds between indoor and outdoor air. Additionally, both gas-phase and aerosol-phase compounds linked to third-hand smoke were detected and quantified in a non-smoking movie theater, possibly via moviegoers' clothes and breath.
The physical properties of honey vary, depending on water content, the type of flora used to produce it (pasturage), temperature, and the proportion of the specific sugars it contains. Fresh honey is a supersaturated liquid, containing more sugar than the water can typically dissolve at ambient temperatures. At room temperature, honey is a supercooled liquid, in which the glucose precipitates into solid granules. This forms a semisolid solution of precipitated glucose crystals in a solution of fructose and other ingredients. The density of honey typically ranges between 1.38 and 1.45 kg/L at 20 °C (68 °F).
Sources: en.wikipedia.org
==== Dopamine precursors and related ==== Carbidopa (Lodosyn) – aromatic L-amino acid decarboxylase (AAAD) inhibitor Carbidopa/levodopa (Crexont; IPX-203; IPX203) – combination of carbidopa (aromatic L-amino acid decarboxylase (AAAD) inhibitor) and levodopa (dopamine precursor) [324] Foscarbidopa/foslevodopa (ABBV-951; foslevodopa/foscarbidopa; levodopa/carbidopa prodrug; Produodopa; Vyalev) – combination of foscarbidopa (aromatic L-amino acid decarboxylase (AAAD) inhibitor) and foslevodopa (dopamine precursor) [325] Levodopa (CVT-301; CXG-89; Inbrija) – dopamine precursor and indirect non-selective dopamine receptor agonist [326] Levodopa/benserazide (co-beneldopa) (Madopar, Prolopa) – combination of levodopa (dopamine precursor) and benserazide (aromatic L-amino acid decarboxylase (AAAD) inhibitor) Levodopa/carbidopa extended-release (GSK-587124; IPX-066; Numient; Patrome; Rytary) – combination of levodopa (dopamine precursor) and carbidopa (aromatic L-amino acid decarboxylase (AAAD) inhibitor) [327] Levodopa/carbidopa intraduodenal (ABT-SLV187; carbidopa/levodopa enteral suspension; Duodopa; Duopa; LCIG; levodopa/carbidopa intestinal gel) – combination of levodopa (dopamine precursor) and carbidopa (aromatic L-amino acid decarboxylase (AAAD) inhibitor) [328] Melevodopa/carbidopa (carbidopa/melevodopa; CHF-1512; CNP-1512; GT-1512; levodopa methyl ester/carbidopa; Sirio; V-1512) – combination of melevodopa (dopamine precursor) and carbidopa (aromatic L-amino acid decarboxylase (AAAD) inhibitor) [329]
Most coatings are designed to be microporous in nature, allowing captive moisture within the wall to evaporate outside, whilst not allowing the passage of water to be drawn inside the building, thus largely providing a secondary feature apart from decoration, and that is to weatherproof a wall, and to stop damp forming inside the building. These coatings are intended for on-site application and do not include "factory-applied coatings for building products such as vinyl siding or aluminium window frames [that] may ultimately be used for architectural end-uses".
Although the following examples illustrate the diversity of point-mutation–mediated disorders, there are over 300,000 such mutations recorded in HGMD and over 1,000,000 variants in ClinVar, reflecting the vast spectrum of human point mutations.
Sources: en.wikipedia.org
== The Monterays era (2002–present) == In January 2002, Dan Elliott invited Ron to take Jack Abert's place in The Monterays. Ron moved from Bass to Lead Guitar with the departure of Dave Moziak in 2005. The Monterays perform around 100 shows a year and are working on a new album. Ron and his son Ronnie Dark were part of the pit band for East Syracuse-Minoa's production of "Grease" (performed February 9 and 10, 2007) The Monterays were the lead in band for the 2007 Taste of Syracuse SAMMY (Syracuse Area Music Awards) Pre-Awards Show (held on June 1, 2007) Also, Ron and The Monterays were one of the featured performers at the Syracuse Nationals (July 21 and 22, 2007). The Monterays performed on the Stan Colella Stage at the New York State Fair A re-recorded version of "Seaweed" by The RLB was used as the closing theme to Around the Tracks, the auto racing program hosted by Joe Marotta and broadcast on WTLA AM (April 2008 – January 2009). Ron is the network announcer for his son Ronnie Dark's radio program The Wax Museum with Ronnie Dark, broadcast Sunday nights 7–10 pm on LOVE RADIO WVOA 87.7 FM (and on the internet at http://www.wvoaradio.com/listenonline.html) The Monterays appeared with Gary Lewis & the Playboys and The Tokens at the Broome County Veterans Arena on August 29, 2009. The Monterays performed with The Tokens, The Teenagers, The Coasters and The Chiffons as part of the Old School Doo Wop Concert at the Landmark Theater, Syracuse, NY on May 9, 2014.
Merck Foundation - founded in 1957, the foundation has donated over $1 billion to charitable causes to promote health equity. In 2012, the foundation ended its donations to the Boy Scouts of America citing its discrimination against gay people. Patient assistance programs to offer access to pharmaceuticals to those unable to afford its medications. Provides funding to Hilleman Laboratories, an India-based non-profit research organization dedicated to the development of low-cost vaccines for use in developing countries. Merck for Mothers prevents maternal mortality. Merck produces Mectizan (ivermectin), an anti-parasitic medicine traditionally used to treat onchocerciasis, solely for donation to people in Africa, Latin America, and Yemen. The donation program has significantly reduced the incidence of the disease.
Hormonal therapy in oncology is hormone therapy for cancer and is one of the major modalities of medical oncology (pharmacotherapy for cancer), others being cytotoxic chemotherapy and targeted therapy (biotherapeutics). It involves the manipulation of the endocrine system through exogenous or external administration of specific hormones, particularly steroid hormones, or drugs which inhibit the production or activity of such hormones (hormone antagonists). Because steroid hormones are powerful drivers of gene expression in certain cancer cells, changing the levels or activity of certain hormones can cause certain cancers to cease growing, or even undergo cell death. Surgical removal of endocrine organs, such as orchiectomy and oophorectomy can also be employed as a form of hormonal therapy. Hormonal therapy is used for several types of cancers derived from hormonally responsive tissues, including the breast, prostate, endometrium, and adrenal cortex. Hormonal therapy may also be used in the treatment of paraneoplastic syndromes or to ameliorate certain cancer- and chemotherapy-associated symptoms, such as anorexia. Perhaps the most familiar example of hormonal therapy in oncology is the use of the selective estrogen-response modulator tamoxifen for the treatment of breast cancer, although another class of hormonal agents, aromatase inhibitors, now have an expanding role in that disease.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.